Conclusion of non-exclusive drug rebate agreements pursuant to § 130a para. 8 SGB V by means of an open-house model for the active ingredient Natalizumab (ATC code according to WHO: L04AG03)

This tender, originating from Germany and published via TED, relates to the conclusion of discount agreements for pharmaceuticals, specifically excluding existing rebate agreements under § 130a Abs. 8 SGB V. The procurement operates via an 'open-house model' and focuses on the active ingredient Natalizumab (ATC code according to W - indicating a specific classification). The contracting authority, likely a statutory health insurance fund or a similar healthcare entity, is seeking to negotiate favorable pricing for this specific medication. The open-house model suggests that manufacturers or suppliers can join the agreement at any time under predefined conditions. The focus on Natalizumab, an immunosuppressive drug often used for conditions like Crohn's disease and multiple sclerosis, indicates a targeted approach to cost management for a high-value medication. Bidders will be pharmaceutical manufacturers or authorized distributors. The tender aims to secure cost-effective supply of Natalizumab while adhering to German pharmaceutical regulations and competitive tendering principles.